Endocrine Abstracts

Since its introduction as an imaging agent in humans in 2011, Ga PSMA PET CT has been rapidly embraced clinically for the imaging of prostate cancer both in the setting of biochemical failure and as a staging procedure. The increased sensitivity of the technique in comparison to previously available imaging modalities, and the startling images, have led to a paradigm shift in the treatment of prostate cancer, particularly in the setting of biochemical failure. This talk will give an overview of the evolving evidence for the use of Ga PSMA in prostate cancer and discuss the need for ongoing research into a promising technique that has turned the management of prostate cancer on its head in recent years.